Compare WVE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | DRUG |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.8M | 778.4M |
| IPO Year | 2015 | 2020 |
| Metric | WVE | DRUG |
|---|---|---|
| Price | $3.88 | $49.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $18.53 | ★ $166.78 |
| AVG Volume (30 Days) | ★ 2.8M | 68.0K |
| Earning Date | 11-09-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | $20.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $3.56 | $48.94 |
| 52 Week High | $21.73 | $123.75 |
| Indicator | WVE | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 26.75 |
| Support Level | N/A | N/A |
| Resistance Level | $6.33 | $78.35 |
| Average True Range (ATR) | 0.21 | 2.85 |
| MACD | -0.02 | -0.69 |
| Stochastic Oscillator | 38.99 | 14.04 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.